GH - Guardant Health, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.27
-2.49 (-3.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close67.76
Open67.14
Bid64.05 x 800
Ask71.00 x 1400
Day's Range63.83 - 67.87
52 Week Range31.01 - 112.22
Volume1,510,609
Avg. Volume1,266,589
Market Cap6.068B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est115.80
Trade prices are not sourced from all markets
  • Bay Area biotech unicorn's stock plunges after IPO hits low end of targets
    American City Business Journals

    Bay Area biotech unicorn's stock plunges after IPO hits low end of targets

    The San Francisco company's IPO is the latest sign that the market for IPOs is weakening at the end of what had been a very active year.

  • Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

    Is (GH) Outperforming Other Medical Stocks This Year?

  • 3 Digital Health Stocks Soaring Amid Skepticism Over IPOs
    Investopedia

    3 Digital Health Stocks Soaring Amid Skepticism Over IPOs

    Amid rising investor disillusionment with young, money losing tech companies, three digital health firms that have gone public in recent years are thriving, and have seen their stocks soar as much as 75% in 2019, dramatically outpacing the broader market. Indeed, the bright prospects for digital health have sparked a rash of new startups that are likely to lead to new round of IPOs in the next several years as they seek to expand in the burgeoning industry. Digital health providers that are well positioned to keep growing - and thus outrun the market -include cloud computing company Veeva Systems Inc. (VEEV), with a $22.4 billion market value, whose shares have returned about 60% year-to-date (YTD), compared to the S&P 500s 14.8% increase.

  • We're Not Worried About Guardant Health's (NASDAQ:GH) Cash Burn
    Simply Wall St.

    We're Not Worried About Guardant Health's (NASDAQ:GH) Cash Burn

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

    BARCELONA, Spain, Sept. 28, 2019 -- Guardant Health and the National Cancer Center Hospital East will present data at the European Society of Medical Oncology (ESMO) conference.

  • Exact Sciences Gets FDA Nod for Label Expansion of Cologuard
    Zacks

    Exact Sciences Gets FDA Nod for Label Expansion of Cologuard

    Exact Sciences (EXAS) gets FDA approval for use of its noninvasive colorectal cancer screening test, Cologuard, in eligible average-risk individuals aged 45 years or older.

  • SoftBank Needs a Different IPO After WeWork Slip
    Bloomberg

    SoftBank Needs a Different IPO After WeWork Slip

    (Bloomberg Opinion) -- SoftBank Group Corp. and its Vision Fund need another win. And they need it fast.With news that U.S. rental office company WeWork  – formally known as The We Company – looks set to delay its IPO, we can see just how dependent SoftBank supremo Masayoshi Son’s empire was on this one exit to keep the Japanese company’s hit machine ticking along. SoftBank Vision Fund has been a major investor in some of this year’s most significant listings. Uber Technologies Inc. and Slack Technologies Inc. were among them. Both have fallen this quarter, dragging down the value of the Fund.There is a pattern to how the Vision Fund keeps returns climbing. Buy in at a later round of a startup’s funding, list the company a year or two later, and book the mark-to-market gains.Sounds simple, except for the one-two punch that follows: SoftBank, like most pre-IPO investors, is generally locked in and can’t cash out that profit for at least a year. Additionally, IPO shares have a tendency to perform badly in their first year. For SoftBank and the Vision Fund, that means quick gains turn to slow public-market losses that need to be booked every period, hurting returns in subsequent quarters.To paper over these losses, the Fund can book gains by bringing its next hot offering to market. That means that as long as there’s a healthy IPO each quarter, the pain from public-market declines can be squelched. So the model becomes: IPO gain, public-market losses, IPO gain. And around again.With WeWork, however, the merry-go-round risks turning into musical chairs. The game needs IPOs on the floor or the music stops. Had WeWork gone public before Sept. 30, and at a healthy premium to the various prices SoftBank paid through its funding rounds, then such paper profits likely would have covered over losses caused by the 26% decline in Uber’s shares so far this quarter and the 30% drop in those for Slack.As Bloomberg’ s Gillian Tan wrote earlier this month, SoftBank and its affiliates own around 29% of WeWork. Should the $47 billion valuation at which SoftBank most-recently bought in turn into the current whisper number of $15 billion, then SoftBank and the Fund could be set to lose as much as $9.28 billion right out of the gate.(4)That would result in an unusual IPO loss, drag down the Fund, and ruin the quarterly model. So it makes sense that SoftBank wants to delay WeWork’s IPO, at least until after Sept. 30. WeWork responded to reports of this delay by saying it expects to complete the IPO by the end of this year.Assuming that there’s no other basis for revaluation, such as a new equity round, the Vision Fund can still contend that WeWork is worth $47 billion when it closes its books at the end of this month.But that doesn’t solve the possibility of the Vision Fund posting a loss this quarter thanks to slides in Uber and Slack. One listed portfolio company, Ping An Good Doctor (aka Ping An Healthcare and Technology Co.), was up 39% in Hong Kong as of Tuesday morning, netting a gain of around $110 million to the Vision Fund. Others have fallen, including Guardant Health Inc. (-13%) and ZhongAn Online P&C Insurance Co. (-8.6%).  I believe that this leaves SoftBank Vision Fund with little choice but to enact a two-pronged strategy. First, take a “big bath(3)” for the September quarter and get the bad news behind it. Second, hurry along the IPOs of the other unicorns in its stable.ByteDance, the hugely popular Chinese video content platform, is currently the world’s most valuable startup at $75 billion, according to CB Insights. That’s followed by Chinese ride-hailing provider Didi Chuxing at $56 billion. I don’t think either is ready to IPO in the next month or two, but there’s always a chance ByteDance may decide to list before a slowdown in the Chinese economy starts to show up in its growth metrics.There are also some smaller fruit about to ripen. South Korean e-commerce company Coupang and U.S. food delivery provider DoorDash Inc. could find favor among IPO investors. Southeast Asian transport and services startup Grab Holdings Inc. would also be very popular, but I sense they want to spend a little more time building the non-transport offerings before pitching an IPO. Then there is Son’s plan to relist British semiconductor designer ARM Holding Plc, which would likely be a success because of its central role in the global technology sector.Despite the troubles with WeWork, SoftBank still has a strong team of highly valued startups on its roster. But they’re not much good to the Vision Fund if they’re sitting on the bench.(1) The exact scale of any loss would depend on how SVF has valued preferred shares acquired in earlier rounds. This figure assumes the Fund raised valuations in subsequent funding rounds.(2) Big Bath refers to the concept of collating lots of bad news in one quarter so that a company can put it all in the past and move on. Often seen as manipulation, I'd argue this can actually be a healthy strategy because it allows investors and management to return their focus to building the company.To contact the author of this story: Tim Culpan at tculpan1@bloomberg.netTo contact the editor responsible for this story: Patrick McDowell at pmcdowell10@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Tim Culpan is a Bloomberg Opinion columnist covering technology. He previously covered technology for Bloomberg News.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.

  • Motley Fool

    3 Stocks Poised for Huge Growth Over the Next Decade

    These forward-looking companies are riding trends in consumer spending, cloud computing, and cancer screening.

  • 3 Top Stocks to Buy in September
    Motley Fool

    3 Top Stocks to Buy in September

    Summer is winding down. But these three stocks should be hot for a long time to come.

  • Here's Why Guardant Health Shares Are Sliding Today
    Motley Fool

    Here's Why Guardant Health Shares Are Sliding Today

    Investors worried about a couple of insider trades put pressure on the stock price.

  • The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health
    Zacks

    The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

    The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

  • 3 Cancer Treatment Stocks to Enrich Your Portfolio
    Zacks

    3 Cancer Treatment Stocks to Enrich Your Portfolio

    Investments in cancer therapies are expected to rise almost $250 billion by 2023, from $150 billion in 2018. Thus, companies that are coming up with innovative methods to cure this malaise are great investment choices.

  • GuruFocus.com

    Guardant Health Inc (GH) Chairman, President and COO Amirali Talasaz Sold $5.1 million of Shares

    Chairman, President and COO of Guardant Health Inc (30-Year Financial, Insider Trades) Amirali Talasaz (insider trades) sold 52,715 shares of GH on 08/23/2019 at an average price of $97.63 a share. Continue reading...

  • Motley Fool

    ShockWave Medical and Guardant Health Are Posting Explosive Growth

    These two med-tech stocks raised guidance after posting blowout quarterly results.

  • My 3 Top Healthcare Stocks for Long-Term Investors
    Motley Fool

    My 3 Top Healthcare Stocks for Long-Term Investors

    They're pioneers. They're innovators. And they should continue to be huge winners for investors with long-term perspectives.

  • Motley Fool

    Winners and Losers in Healthcare This Quarter

    ShockWave and Guardant reported fantastic things, while Abiomed and Inogen dropped precipitously on some scary updates.

  • GuruFocus.com

    Guardant Health Inc (GH) CFO Derek A Bertocci Sold $4.3 million of Shares

    CFO of Guardant Health Inc (30-Year Financial, Insider Trades) Derek A Bertocci (insider trades) sold 42,548 shares of GH on 08/19/2019 at an average price of $100 a share. Continue reading...

  • GuruFocus.com

    Guardant Health Inc (GH) CEO Helmy Eltoukhy Sold $25.4 million of Shares

    CEO of Guardant Health Inc (30-Year Financial, Insider Trades) Helmy Eltoukhy (insider trades) sold 253,699 shares of GH on 08/16/2019 at an average price of $100.21 a share. Continue reading...

  • 5 Top Cancer-Fighting Stocks to Buy Now
    Motley Fool

    5 Top Cancer-Fighting Stocks to Buy Now

    Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.

  • 3 Healthcare Stocks With Rising Expectations
    Motley Fool

    3 Healthcare Stocks With Rising Expectations

    For a few companies, the second half of 2019 will probably work out better than investors dared hope for earlier this year.

  • AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
    Zacks

    AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

    AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

  • Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet
    Zacks

    Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

    Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

  • Why Guardant Health Stock Skyrocketed 21% Today
    Motley Fool

    Why Guardant Health Stock Skyrocketed 21% Today

    Great Q2 results and higher full-year revenue guidance excited investors.